Description
Krabeva 400mg Injection is an anticancer medication. It is used in the treatment of cancer of colon and rectum, non-small cell lung cancer, kidney cancer, brain tumor, ovarian and cervical cancer. It helps to prevent the growth of new blood vessels that feed tumors and stops tumors from growing.
Krabeva 400mg Injection is an effective medicine, first-line option when used together with other cancer medicines. It is given as an infusion. That means you get it through a small needle in your vein or through a port, which is a device placed under your skin. The doctor will decide your dose and duration and will check you for signs of an infusion reaction such as high blood pressure and trouble breathing. You keep taking Krabeva 400mg Injection as long as your disease is controlled and your side effects are manageable. Your doctor will determine whether you should stop taking it or not. You may be advised to check blood pressure and levels of protein in urine while you are taking this medication.
The most common side effects of this medicine include nosebleeds, headache, high blood pressure, rhinitis, protein in urine, change in taste, dry skin, bleeding, lacrimation disorder, back pain, and exfoliative dermatitis. Inform your doctor that you are taking this medication before undergoing any surgical procedure, as the drug has ability to lower the ability of wound healing. Other than this, it also enhances your risk of bleeding thus if you notice any unusual bleeding or bleeding consult with your doctor immediately.
Inform your doctor if you are pregnant, planning pregnancy or breastfeeding. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using.
We have strong global networks in Africa, Europe, United Kingdom, United States, Chile, Peru, Ethiopia, Romania, China, Japan, Russia, Ukraine, Dubai, Unites Arab Emirates, Thailand, Vietnam, Middle East and South East Countries.
Explore the more products anti cancer
Reviews
There are no reviews yet.